Toshinori Hinoue

Van Andel Institute — United States

Medicine · Health Sciences

56h-index65.8kcitations226works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(94), Cancer Immunotherapy and Biomarkers(90), Epigenetics and DNA Methylation(45), Cancer Genomics and Diagnostics(44), Multiple and Secondary Primary Cancers(43)

Publications187 total

Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
UNC Libraries·2025Open Access
Figure S9 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S5 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S6 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S8 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S3 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S2 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S10 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S4 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S12 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure S1 from DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer
2025Open Access
Table S1, S2 from DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer
2025Open Access
High-coverage allele-resolved single-cell DNA methylation profiling reveals cell lineage, X-inactivation state, and replication dynamics
Nature Communications·2025· 5 citedOpen Access
Abstract 6608: Integrating HCMI models and tumors with CCLE and TCGA: Advancing cancer modeling and precision oncology
Cancer Research·2025
Abstract 6358: Single cell transcriptional dynamics in the HCMI cancer model collection
Cancer Research·2025
Abstract 4005: Integrative clinical and molecular characterization of an international community resource of organoid models of human cancer
Cancer Research·2025
page 1 of 10Next →

Frequent Co-authors

Peter W. Laird(38), Andrew D. Cherniack(24), Katherine A. Hoadley(21), Hui Shen(18), Rehan Akbani(18), John N. Weinstein(15), Gad Getz(14), Reanne Bowlby(12), Joshua M. Stuart(12), Ina Felau(12), Daniel J. Weisenberger(11), David J. Kwiatkowski(10), Jean C. Zenklusen(10), Jaegil Kim(10), Mauro A. A. Castro(10), John A. Demchok(9), Jay Bowen(9), Hikmat Al‐Ahmadie(9), A. Gordon Robertson(9), Gordon B. Mills(9)